加载中
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
前收盘价
US$21.11
+US$0.66 · +3.23%
盘中时间采用ET。市场数据可能有所延迟。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日内区间
当前US$21.11
52周区间
当前US$21.11
盘中时间采用ET。市场数据可能有所延迟。
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.
日内区间
当前US$21.11
52周区间
当前US$21.11
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 33.5万 USD | — | — | — | — |
| 毛利 | −33.5万 USD | — | — | — | — |
| 研究与开发 | 3873.2万 USD | 3501.6万 USD | 2982.1万 USD | 2048.4万 USD | 855.3万 USD |
| 销售、一般及管理费用 | 2160.9万 USD | 1500.2万 USD | 1112.1万 USD | 1005.6万 USD | 654.2万 USD |
| 营业费用 | 6034.1万 USD | 5031.2万 USD | 4122.2万 USD | 3055.4万 USD | 1510万 USD |
| 利息收入 | 262.5万 USD | 262.8万 USD | 189万 USD | 85.8万 USD | 9 USD |
| 利息支出 | 46.3万 USD | 71.7万 USD | 72.3万 USD | — | 9000 USD |
| 折旧和摊销 | 33.5万 USD | 31.5万 USD | 31.5万 USD | 4.7万 USD | 1.9万 USD |
| 营业利润 | −6067.6万 USD | −5031.2万 USD | −4122.2万 USD | −3055.4万 USD | −1510万 USD |
| 净利润 | −4825.8万 USD | −3896.1万 USD | −3558.7万 USD | −2245.6万 USD | −920.2万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$48.83
上涨空间 131.31%价格历史记录不可用
最高：US$65.00平均的：US$48.83最低：US$39.00报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB806.7万0.08%108.2亿 USD0.44%US$206.49+3.00%
AdvisorShares Psychedelics ETFPSIL194.29万4.15%4685.29万 USD1.84%US$21.765+3.69%
iShares MSCI Ireland ETFEIRL107.9万1.44%7459.97万 USD0.50%US$78.50-1.14%
Virtus Biotech Clinical Trials ETFBBC30.73万0.75%4099.65万 USD0.65%US$44.1456+2.08%
Invesco Nasdaq Biotechnology ETFIBBQ10.8万0.10%1.12亿 USD0.19%US$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB5.57万0.06%9320.36万 USD1.19%US$110.98+5.68%
First Trust IPOX Europe Equity Opportunities ETFFPXE1.1万0.23%472.63万 USD0.70%US$31.665-2.15%iShares Biotechnology ETFIBBAdvisorShares Psychedelics ETFPSILiShares MSCI Ireland ETFEIRLVirtus Biotech Clinical Trials ETFBBCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBFirst Trust IPOX Europe Equity Opportunities ETFFPXEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
